BACKGROUND: Given the increasing lifespan of the elderly and the higher proportion of older people in the global population, the incidence rate of neurodegenerative diseases is increasing. The aim of this study is to evaluate, by means of computer simulations, developments in the costs of treating and caring for people suffering from Alzheimer's disease (AD) in the EU 28 by 2080, while assuming the introduction of drug administrations at various disease stages. METHODS: Impact analysis leverages a mathematical model that compares five different population development scenarios when introducing different types of drugs to the scenarios but without changing the treatment. Changes in the economic burden are considered as of 2023, when new drugs are expected to enter the market. FINDINGS: The results of the simulations show that by prolonging the length of a person's 'stay' in the Mild, Moderate, or Severe stage, the total cost of care for all persons with AD will increase by 2080. For individual scenarios, the percentage of patients and costs increased as follows: Mild by one year, by 10.61%; Mild by two years, by 17.73%; Moderate by one year, by 16.79%; Moderate by two years, by 34.88%; and Severe by one year, by 23.79%. The change in cost development when prolonging the stay in the Mild cognitive impairment stage (by lowering the incidence by 10%, 30%, or 50%) reduced the cost (by 4.88%, 16.78% and 32.48%, respectively). INTERPRETATION: The results unambiguously show that any intervention prolonging a patient's stay in any stage will incur additional care costs and an increase in the number of persons with AD. Therefore, extending lifespan is important in terms of improving the quality of life of patients, and the introduction of new drugs must consider the additional costs imposed upon society.

Faculty of Informatics and Management University of Hradec Králové Hradec Králové Czech Republic

Faculty of Science University of Hradec Králové Hradec Králové Czech Republic

Zobrazit více v PubMed

Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s disease. The Lancet. 1997;349(9064):1546–1549. 10.1016/S0140-6736(96)10203-8 PubMed DOI

Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46(1):130–135. 10.1212/WNL.46.1.130 PubMed DOI

Boada M, Pena-Casanova J, Bermejo F, Guillen F, Hart W, Espinosa C, et al. Costs of health care resources of ambulatory-care patients diagnosed with Alzheimer’s disease in Spain. Medicina clinica. 1999;113(18):690–695. PubMed

Ernst RL, Hay JW. The US economic and social costs of Alzheimer’s disease revisited. American Journal of Public Health. 1994;84(8):1261–1264. 10.2105/AJPH.84.8.1261 PubMed DOI PMC

Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. Cognitive function and the costs of Alzheimer disease: an exploratory study. Archives of neurology. 1997;54(6):687–693. 10.1001/archneur.1997.00550180013006 PubMed DOI

Schwarzkopf L, Menn P, Kunz S, Holle R, Lauterberg J, Marx P, et al. Costs of care for dementia patients in community setting: an analysis for mild and moderate disease stage. Value in Health. 2011;14(6):827–835. 10.1016/j.jval.2011.04.005 PubMed DOI

Dodel R, Belger M, Reed C, Wimo A, Jones RW, Happich M, et al. Determinants of societal costs in Alzheimer’s disease: GERAS study baseline results. Alzheimer’s & Dementia. 2015;11(8):933–945. 10.1016/j.jalz.2015.02.005 PubMed DOI

Innovation for active and healthy ageing: European summit on innovation for active and healthy ageing, Brussels, 9-10 March 2015: final report. Brussels: European Commission; 2015.

Marešová P, Zahálková V. The economic burden of the care and treatment for people with Alzheimer’s disease: the outlook for the Czech Republic. Neurological Sciences. 2016;37(12):1917–1922. 10.1007/s10072-016-2679-6 PubMed DOI

Maresova P, Mohelská H, Dolejs J, Kuca K. Socio-economic aspects of Alzheimer’s disease. Current Alzheimer Research. 2015;12(9):903–911. 10.2174/156720501209151019111448 PubMed DOI

Maresova P, Mohelska H, Kuca K. Social and family load of Alzheimer’s disease. Applied Economics. 2016;48(21):1936–1948. 10.1080/00036846.2015.1111986 DOI

Arizaga RL. Epidemiology of dementia. Dementia: a multidisciplinary approach. 2005;2:7–17.

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s & dementia. 2007;3(3):186–191. 10.1016/j.jalz.2007.04.381 PubMed DOI

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. The lancet. 2006;366(9503):2112–2117. 10.1016/S0140-6736(05)67889-0 PubMed DOI PMC

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s & Dementia. 2013;9(1):63–75. 10.1016/j.jalz.2012.11.007 PubMed DOI

Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer’s disease in Japan. Dementia and geriatric cognitive disorders. 2002;13(1):33–39. 10.1159/000048631 PubMed DOI

Gustavsson A, Green C, Jones RW, Förstl H, Simsek D, de Vulpillieres FdR, et al. Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer’s disease. Alzheimer’s & Dementia. 2017;13(3):312–321. 10.1016/j.jalz.2016.12.005 PubMed DOI

Keogh-Brown MR, Jensen HT, Arrighi HM, Smith RD. The impact of Alzheimer’s disease on the Chinese economy. EBioMedicine. 2016;4:184–190. 10.1016/j.ebiom.2015.12.019 PubMed DOI PMC

Suh GH. Modeling the cost-effectiveness of galantamine for mild to moderately severe alzheimer’s disease in Korea. Value in Health. 2009;12:S49–S54. 10.1111/j.1524-4733.2009.00627.x PubMed DOI

Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2017. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017. PubMed PMC

Tomaskova H, Kuhnova J, Cimler R, Dolezal O, Kuca K. Prediction of population with Alzheimer’s disease in the European Union using a system dynamics model. Neuropsychiatric Disease and Treatment. 2016;12:1589 10.2147/NDT.S107969 PubMed DOI PMC

Cimler R, Tomaskova H, Kuhnova J, Dolezal O, Pscheidl P, Kuca K. Numeric, Agent-based or System dynamics model? Which modeling approach is the best for Alzheimer’s disease population simulation? Current Alzheimer Research. 2017. Submitted. PubMed

Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133–42 10.1212/WNL.56.9.1133 PubMed DOI

Eldon Spackman D, Kadiyala S, J Neumann P, L Veenstra D, D Sullivan S. Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS. Current Alzheimer Research. 2012;9(9):1050–1058. 10.2174/156720512803569046 PubMed DOI PMC

O’Bryant SE, Humphreys JD, Smith GE, Ivnik RJ, Graff-Radford NR, Petersen RC, et al. Detecting dementia with the mini-mental state examination in highly educated individuals. Archives of neurology. 2008;65(7):963–967. 10.1001/archneur.65.7.963 PubMed DOI PMC

Maresova P, Kuca K, Dolejs J. Call for a uniform strategy of Alzheimer’s disease costs collection: a review and meta-analysis. Journal of Alzheimer’s Disease (Submitted). 2018. 10.3233/JAD-171028 PubMed DOI

Mesterton J, Wimo A, Langworth S, Winblad B, Jonsson L, et al. Cross sectional observational study on the societal costs of Alzheimer’s disease. Current Alzheimer Research. 2010;7(4):358–367. 10.2174/156720510791162430 PubMed DOI

Skoldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease-a simulation study. Current Alzheimer Research. 2013;10(2):207–216. 10.2174/1567205011310020011 PubMed DOI

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford university press; 2015.

Anderson R, Knapp M, Wittenberg R, Handels R, Schott JM. Economic Modelling of Disease-Modifying Therapies in Alzheimer’s Disease. Doctoral dissertation, Institute of Neurology, London;2018.

Wimo A, Jonsson L. Cost of Illness and Burden of Dementia in Europe Prognosis to 2030. Alzheimer Europe. 2009.

Prince MJ. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International; 2015.

Wimo A, Jonsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia in 2010. Alzheimer’s & Dementia 9: 1–11;2013. 10.1016/j.jalz.2012.11.006 PubMed DOI

Smith D, Gravelle H. The Practice of Discounting Economic Evaluation of Health Care Interventions. International journal of technology assessment in health care 172,236–243;2001. http://eprints.whiterose.ac.uk/255/1/gravelleh6.pdf 10.1017/S0266462300105094 PubMed DOI

Discount Rate [online]. New York; York Health Economics Consortium 2016. http://www.yhec.co.uk/glossary/discount-rate/

Nonpharmacological intervention therapies for dementia: potential break-even intervention price and savings for selected risk factors in the European healthcare system

Benefits of the Use of Mobile Applications for Learning a Foreign Language by Elderly Population

Amaryllidaceae Alkaloids of Belladine-Type from Narcissus pseudonarcissus cv. Carlton as New Selective Inhibitors of Butyrylcholinesterase